insulins human
Preclinical
Eli Lillyinsulins human is one of 67 therapeutic programs targeting Type 2 Diabetes. It is currently in Preclinical.
2
Indications
0
Total Trials
0
Active Trials
66
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
165 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Routine Treatment
GSKPreclinical
Sulfonylureas
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for insulins human. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company